Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Dahlia Henry"'
Autor:
Denis M. Schewe, Lennart Lenk, Fotini Vogiatzi, Dorothee Winterberg, Annika V. Rademacher, Swantje Buchmann, Dahlia Henry, Anke K. Bergmann, Gunnar Cario, Michael C. Cox
Publikováno v:
Blood Advances, Vol 3, Iss 22, Pp 3499-3502 (2019)
Externí odkaz:
https://doaj.org/article/58ba6a553f9542ed81a6ba924b3717d7
Autor:
Marc Ladanyi, Bob T. Li, Jennifer Kherani, Elena Ivanova, Arrien A. Bertram, Ezra Y. Rosen, Elaine M. Kelley, Jieun Son, Marina S.D. Milan, Jaclyn F. Hechtman, Romel Somwar, Kevin Ebata, Alexander Drilon, Melissa Lynne Johnson, Sarah E. Clifford, Jenna E. Scanlon, Barry S. Taylor, Geoffrey R. Oxnard, Eric Gladstone, S Michael Rothenberg, Elizabeth Olek, Monika A. Davare, Binoj Nair, Pasi A. Jänne, Mika Lin, Lynette M. Sholl, Morana Vojnic, Dahlia Henry
Publikováno v:
Clin Cancer Res
Purpose: The RET proto-oncogene encodes a receptor tyrosine kinase that is activated by gene fusion in 1%–2% of non–small cell lung cancers (NSCLC) and rarely in other cancer types. Selpercatinib is a highly selective RET kinase inhibitor that ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c3eedfba373fe8e1440677846f5c39b
https://doi.org/10.1158/1078-0432.ccr-20-2278
https://doi.org/10.1158/1078-0432.ccr-20-2278
Autor:
Ulrike Gerdemann, Steve Smith, Michael C. Cox, A. Lindsay Frazier, Peter M. Anderson, Sandya Govinda Raju, Julia Glade Bender, S. Michael Rothenberg, Alberto S. Pappo, Michael V. Ortiz, Dahlia Henry, Stéphanie Proust
Publikováno v:
JCO Precision Oncology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d41441b14477d4a1737a40742e7259e
https://doi.org/10.1200/po.19.00401
https://doi.org/10.1200/po.19.00401
Autor:
Jochen K. Lennerz, Jennifer Kherani, Ryan P. Frazier, Trisha Chung, Sandya Govinda Raju, Lori J. Wirth, Dora Dias-Santagata, Dahlia Henry, Peter M. Sadow, S. Michael Rothenberg
Publikováno v:
Thyroid
Background: Anaplastic thyroid carcinoma (ATC) remains one of the most challenging malignancies to treat in the modern era. Most patients present with or develop recurrent/metastatic incurable disease with poor response rates to conventional chemothe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a5b8b9b8e0588d0590a9b0edb99b291
http://europepmc.org/articles/PMC7482117
http://europepmc.org/articles/PMC7482117
Autor:
Geoffrey R. Oxnard, Satoshi Yoda, Bruce G. Robinson, Eliana B. Gomez, Sarah-Jane Dawson, S. Michael Rothenberg, Justin F. Gainor, Dahlia Henry, Oliver Gautschi, Christine Khoo, Stephen Q. Wong, Edward Y. Zhu, Andrew T. Metcalf, Louis Stancato, Brian B. Tuch, Barbara J. Brandhuber, Steve Andrews, Jessica J. Lin, Lavinia Tan, Kevin Ronald Condroski, Vivek Subbiah, Lecia V. Sequist, Wayne Blosser, James F. Blake, Joshua Ballard, Kolakowski Gabrielle R, Kevin Ebata, Alexander Drilon, Benjamin Solomon, Michele Nguyen, Sebastian Hollizeck
Publikováno v:
Journal of Thoracic Oncology. 15:541-549
Introduction Novel rearranged in transfection (RET)-specific tyrosine kinase inhibitors (TKIs) such as selpercatinib (LOXO-292) have shown unprecedented efficacy in tumors positive for RET fusions or mutations, notably RET fusion-positive NSCLC and R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::742f3d3d111a3f191f93aa96d410395b
https://doi.org/10.1016/j.jtho.2020.01.006
https://doi.org/10.1016/j.jtho.2020.01.006
Autor:
Mark Schreyer, Mark G. Kris, David M. Hyman, S. Michael Rothenberg, Natasha Rekhtman, Robin Guo, Robert J. Young, Alexander Drilon, Jason C. Chang, Paolo Cotzia, Dahlia Henry
Publikováno v:
JCO Precision Oncology. :1-6
The development of leptomeningeal metastases is a poor prognostic factor in patients with advanced cancers.1–3 In non–small-cell lung cancers (NSCLCs), median overall survival of patients from the diagnosis of leptomeningeal disease is 1 to 2 mon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8680c8b5cae2cd39035c28573331e9a2
https://doi.org/10.1200/po.19.00021
https://doi.org/10.1200/po.19.00021
Autor:
Shunsuke, Kato, Junya, Fujimura, Yumi, Nozaki, Shigeo, Yamaguchi, Tatsuya, Takagi, Takuo, Hayashi, Tsuyoshi, Saito, Dahlia, Henry, Nora, Ku, Yoshiyuki, Suehara
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 46(10)
Tropomyosin-related kinase(TRK)fusion proteins are oncogenic drivers in multiple tumors in adults and children.Larotrectinib, an orally administered selective TRK inhibitor approved in the US, exhibits inhibitory activity against tumors harboring TRK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7486fe1ad2af89fe2e7d3bf43e2a87f5
https://pubmed.ncbi.nlm.nih.gov/31631147
https://pubmed.ncbi.nlm.nih.gov/31631147
Autor:
Robin, Guo, Mark, Schreyer, Jason C, Chang, S Michael, Rothenberg, Dahlia, Henry, Paolo, Cotzia, Mark G, Kris, Natasha, Rekhtman, Robert J, Young, David M, Hyman, Alexander, Drilon
Publikováno v:
JCO precision oncology. 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1f11ae386c658496ce808c5bef7ffda1
https://pubmed.ncbi.nlm.nih.gov/31485557
https://pubmed.ncbi.nlm.nih.gov/31485557
Autor:
Shannon L. Winski, A. Drilon, Karyn Bouhana, Vamsidhar Velcheti, Dahlia Henry, Mark E. Burkard, Naifa L. Busaidy, Stephen M. Rothenberg, Maria E. Cabanillas, D. Hartley, R. Hamor, Barbara J. Brandhuber, Steve Andrews, R. D. Wallace, S. Rhodes, S. Stock, V. Lauriault, Vivek Subbiah, S. Corsi-Travali, Lori J. Wirth, Brian B. Tuch, M.G. Muni Reddy, Steven J. Smith, Kevin Ebata
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 29(8)
Background Alterations involving the RET kinase are implicated in the pathogenesis of lung, thyroid and other cancers. However, the clinical activity of multikinase inhibitors (MKIs) with anti-RET activity in RET-altered patients appears limited, cal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f036f69cc0069ad242760eeaf45c4c35
https://pubmed.ncbi.nlm.nih.gov/29860429
https://pubmed.ncbi.nlm.nih.gov/29860429
Autor:
Dahlia Henry, Alberto S. Pappo, Julia Glade Bender, Ulrike Gerdemann, Michael V. Ortiz, Hyoung Jin Kang, Steven J. Smith, Young Ah Lee, A. Lindsay Frazier, Michael C. Cox, Sandya Govinda Raju, Stephen M. Rothenberg
Publikováno v:
Journal of Clinical Oncology. 37:10045-10045
10045 Background: Genomic alterations of RET kinase, including chromosomal fusions and activating point mutations, have been identified as oncogenic drivers in pediatric and adult cancers. Multikinase inhibitors have modest activity against RET-alter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af999e9146b8dc0ca61869556e30e3c8
https://doi.org/10.1200/jco.2019.37.15_suppl.10045
https://doi.org/10.1200/jco.2019.37.15_suppl.10045